The FDA approves the revision of the application of new drug for Ridaforolimus, an inhibitor of mTOR in phase of research.
Whitehouse Station, N.J., and Cambridge, mass., October 2011- Merck (NYSE:MRK), known as MSD outside of United States and Canada, and ARIAD Pharmaceuticals, Inc., (NASDAQ:ario), announced on Monday that the Food and Drug Administration (FDA) has accepted the request review of new drug for ridaforolimus, an inhibitor of mTOR oral stage of development for the treatment of sarcomas metastatic tissues soft or bone in patients who had submitted a favourable response to chemotherapy. The FDA has assigned a classification of standard revision for this request.
MSD and ARIAD announced beforehand that the European Medicines Agency had accepted the application for marketing authorisation for ridaforolimus. As part of an exclusive license agreement with ARIAD, MSD is responsible for the development and marketing at the level of ridaforolimus in Oncology ARIAD aims to ridaforolimus in the United States copromocionar.
Sarcoma about
Sarcomas are a group of cancers of the connective tissue of the body for which currently there are limited treatment options. Sarcomas can arise anywhere in the body and are divided into two main groups: tumors of the bone and soft tissue sarcoma.
About Ridaforolimus
Ridaforolimus is a small molecule in investigation phase, the protein mTOR, which acts as a central regulator of protein synthesis, cell proliferation, the progression of the cycle and cell survival and integrates signals from proteins such as PI3K inhibitor, selective and potent, AKT and PTEN, known by its neoplastic importance.
Commitment to MSD with oncology
MSD is committed to progress in all aspects of cancer care: prevention, treatment and palliative care. Through robust internal research capabilities, alliances and selective acquisitions and instrumental technologies, MSD hopes to lead the discovery, development and delivery of cancer treatments.
About MSD
Currently MSD is a leader in global health who works to contribute to global health. MSD is known as Merck & Co., Inc. in United States and Canada. Through our medicines, vaccines, biological therapies, consumer products and veterinarians, work with our clients operating in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increase access to health services through wide-ranging policies, programs and collaborations.
About ARIAD
ARIAD Pharmaceuticals, Inc. is an emerging oncology company globally focused on the discovery, development and commercialization of medicines to transform the lives of cancer patients. ARIAD approach to drug design based on the structure has led to three candidates from products that target molecularly non–small internally discovered drugs-resistant and difficult to treat cancers, including some forms of leukemia chronic myelogenous, sarcomas of soft tissue and bone and lung cancer.
